Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.06243343494068824 | N/A |
Market Cap | $5.28M | N/A |
Shares Outstanding | 84.53M | 5.98% |
Employees | 0 | N/A |
Shareholder Equity | 1.38M | -27.42% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -6.24 | N/A |
P/S Ratio | 13.51 | N/A |
P/B Ratio | 3.81 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.4140 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $390.76K | N/A |
Earnings | -$572.78K | N/A |
EPS | -0.01 | N/A |
Earnings Yield | -0.1602 | N/A |
Gross Margin | 0.8536 | N/A |
Operating Margin | -1.43 | N/A |
Net income margin | -1.47 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $1.77M | N/A |
Cash on Hand | $143.26K | N/A |
Debt to Equity | 0.5463 | 234.57% |
Current Ratio | 0.6938 | -72.91% |